Found 3603 clinical trials
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
at 13.5 mg on a 2-week-on–therapy and 1-week-off–therapy schedule. With Protocol Amendment 3, the administration schedule will be adjusted, and newly enrolled subjects will
- 80 views
- 14 Dec, 2020
- 35 locations
COVID-19 Treatment Trial: Investigational Medication as a Non-antiviral Immunomodulator
. - Arm A: CD24Fc / Best Available Treatment - Arm B: placebo / Best Available Treatment CD24Fc will be administered as single dose of 480 mg via IV infusion on
- 4012 views
- 17 Jun, 2020
- 4 locations
Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- 51 views
- 22 Feb, 2019
- 1 location
A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of atogepant for the prevention of chronic migraines (PROGRESS)
To evaluate the safety and tolerability of atogepant 30 mg twice per day (BID) and 60 mg once daily for the prevention of chronic migraine (CM).
- 43 views
- 10 May, 2019
- 1 location
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Larazotide for Relief of Persistent Symptoms in Patients with Celiac Disease on a Gluten Free Diet
To assess the efficacy and safety of larazotide 0.25 mg or larazotide 0.50 mg TID versus placebo for the relief of persistent symptoms in adult patients with celiac disease on
- 41 views
- 23 Nov, 2020
- 1 location
A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) on slowing progression of mild cognitive impairment due to Alzheimer's disease
A study for patients with mild cognitive impairment due to Alzheimer's disease with short memory loss.
- 32 views
- 08 Dec, 2020
- 1 location
Phase 3 Study to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
This is a 56-week, placebo controlled study to evaluate the efficacy and safety of the SM04690 injectable suspension 0.07 mg dose in the treatment of knee osteoarthritis (OA). Both patient
- 112 views
- 23 Nov, 2020
- 1 location
A Phase III Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine over 24 Weeks in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease.
This study will enroll approximately 800 patients with moderate to severe COPD in 2 subsets. The 24-week subset will enroll approximately 400 patients randomized 1:1 ensifentrine (3 mg
- 156 views
- 23 Nov, 2020
- 1 location
C3441052 Talapro-3
The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.
- 0 views
- 22 Sep, 2021
- 16 locations
SPROUT - Pediatric Psoriasis - CC-10004 PPSO 003 - US
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis.
- 12 views
- 08 Jul, 2021
- 20 locations